Stockscreener 앱 받기
0.831
6.36%
-0.0564
전일 마감가:
$0.8874
열려 있는:
$0.87
하루 거래량:
546.27K
Relative Volume:
1.03
시가총액:
$64.05M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-2.4821
EPS:
-0.3348
순현금흐름:
$-21.07M
1주 성능:
+2.14%
1개월 성능:
-16.78%
6개월 성능:
-16.53%
1년 성능:
-32.98%
1일 변동 폭
$0.79
$0.90
1주일 범위
$0.7101
$0.93
52주 변동 폭
$0.7101
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.831 | 64.05M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5%Here's What Happened - MarketBeat
From Crisis To Opportunity: How Advances In Immunotherapy Are Shaping The Oncology Sector - MENAFN.COM
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Early-Onset Cancer Trends Spark Interest In Promising Oncology Pipelines - MENAFN.COM
Oncolytics Biotech Inc. - Baystreet.ca
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - Barchart
Oncolytics Biotech's SWOT analysis: pelareorep progress boosts stock outlook - Investing.com
Oncolytics Biotech (TSE:ONC) Sets New 12-Month LowWhat's Next? - MarketBeat
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - The Eastern Progress Online
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 2.1%Should You Sell? - MarketBeat
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - The Eastern Progress Online
Oncolytics Biotech's SWOT analysis: pela's potential buoys speculative stock By Investing.com - Investing.com Nigeria
Oncolytics Biotech's SWOT analysis: pela's potential buoys speculative stock - Investing.com India
Oncolytics Biotech's SWOT analysis: cancer drug developer's stock faces pivotal year - Investing.com
Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial?s New Pancreatic Cancer Cohort - Marketscreener.com
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort - Barchart
Oncolytics Biotech® Reports Completion of Initial Safety Phase E - GuruFocus.com
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - cnhinews.com
Biotech Advances Drive Cancer Research As Global Rates Continue Upward Trend - MENAFN.COM
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference - Quantisnow
Cancer firm Replimune readies $125 million offering - The Pharma Letter
Oncolytics Biotech® to Host Conference Call to Discuss Third Qua - GuruFocus.com
HC Wainwright Has Negative Estimate for ONCY FY2024 Earnings - MarketBeat
HC Wainwright Issues Negative Forecast for TSE:ONC Earnings - MarketBeat
Leede Financial Weighs in on TSE:ONC FY2024 Earnings - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to Moderate Buy Rating by Leede Financial - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Upgraded at Raymond James - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded by Raymond James to Moderate Buy Rating - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Moderate Buy" Rating by Leede Financial - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James - MarketBeat
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):